59 related articles for article (PubMed ID: 10188883)
41. Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin.
Lilly M; Tompkins C; Brown C; Pettit G; Kraft A
Cancer Res; 1990 Sep; 50(17):5520-5. PubMed ID: 2386956
[TBL] [Abstract][Full Text] [Related]
42. Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers.
Sutherland HJ; Lansdorp PM; Henkelman DH; Eaves AC; Eaves CJ
Proc Natl Acad Sci U S A; 1990 May; 87(9):3584-8. PubMed ID: 2333304
[TBL] [Abstract][Full Text] [Related]
43. Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro.
Jones RJ; Sharkis SJ; Miller CB; Rowinsky EK; Burke PJ; May WS
Blood; 1990 Mar; 75(6):1319-23. PubMed ID: 2310830
[TBL] [Abstract][Full Text] [Related]
44. Detection of the Philadelphia chromosome in interphase nuclei.
Arnoldus EP; Wiegant J; Noordermeer IA; Wessels JW; Beverstock GC; Grosveld GC; van der Ploeg M; Raap AK
Cytogenet Cell Genet; 1990; 54(3-4):108-11. PubMed ID: 2265553
[TBL] [Abstract][Full Text] [Related]
45. Effect of the protein kinase C activating agent bryostatin 1 on the clonogenic response of leukemic blast progenitors to recombinant granulocyte-macrophage colony-stimulating factor.
Grant S; Pettit GR; Howe C; McCrady C
Leukemia; 1991 May; 5(5):392-8. PubMed ID: 2033960
[TBL] [Abstract][Full Text] [Related]
46. Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor.
Pendergast AM; Muller AJ; Havlik MH; Clark R; McCormick F; Witte ON
Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5927-31. PubMed ID: 1712111
[TBL] [Abstract][Full Text] [Related]
47. Specific inhibition of cytoplasmic protein tyrosine kinases by herbimycin A in vitro.
Fukazawa H; Li PM; Yamamoto C; Murakami Y; Mizuno S; Uehara Y
Biochem Pharmacol; 1991 Oct; 42(9):1661-71. PubMed ID: 1656993
[TBL] [Abstract][Full Text] [Related]
48. Signal transduction inhibitors as novel anticancer drugs: where are we?
Workman P
Ann Oncol; 1992 Jul; 3(7):527-31. PubMed ID: 1498072
[No Abstract] [Full Text] [Related]
49. Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro.
Gishizky ML; Witte ON
Science; 1992 May; 256(5058):836-9. PubMed ID: 1375394
[TBL] [Abstract][Full Text] [Related]
50. Stimulation by human placental conditioned medium of hemopoietic colony formation by human marrow cells.
Burgess AW; Wilson EM; Metcalf D
Blood; 1977 Apr; 49(4):573-83. PubMed ID: 300256
[TBL] [Abstract][Full Text] [Related]
51. Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors.
Thijsen SF; Schuurhuis GJ; van Oostveen JW; Theijsmeijer AP; van der Hem KG; Odding JH; Dräger AM; Ossenkoppele GJ
Br J Cancer; 1999 Mar; 79(9-10):1406-12. PubMed ID: 10188883
[TBL] [Abstract][Full Text] [Related]
52. Chronic myeloid leukaemia: stem cell derived but progenitor cell driven.
Marley SB; Gordon MY
Clin Sci (Lond); 2005 Jul; 109(1):13-25. PubMed ID: 15966868
[TBL] [Abstract][Full Text] [Related]
53. Differentiation and growth modulation of myeloid leukemia cells by the protein kinase C activating agent bryostatin-1.
Steube KG; Drexler HG
Leuk Lymphoma; 1993 Jan; 9(1-2):141-8. PubMed ID: 8477194
[TBL] [Abstract][Full Text] [Related]
54. The clinical development of the bryostatins.
Clamp A; Jayson GC
Anticancer Drugs; 2002 Aug; 13(7):673-83. PubMed ID: 12187323
[TBL] [Abstract][Full Text] [Related]
55. The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development.
Ruan BF; Zhu HL
Curr Med Chem; 2012; 19(16):2652-64. PubMed ID: 22506770
[TBL] [Abstract][Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
